• Home
  • Resource Library

Resource Library

publications • bibliographies • white papers

All Publications

  • Prevalence of diabetes mellitus in the Netherlands more than doubled in the period 1999-2014Abstract

    OBJECTIVE: To study the trend in the prevalence of diabetes in the Netherlands during the period 1999-2014. DESIGN: Descriptive study of prevalence. METHODS: The prevalence of diabetes during the period 1999-2014 was calculated on the basis of datafrom the PHARMO Database Network, a network of electronic databases that includes data from public pharmacies for 3

    Overbeek JA, van der Heijden AW, Herings RM, Nijpels G. Ned Tijdschr Geneeskd. 2017 161 D673.
  • An evaluation of exact matching and propensity score methods as applied in a comparative effectiveness study of inhaled corticosteroids in asthmaAbstract

    BACKGROUND: Cohort matching and regression modeling are used in observational studies to control for confounding factors when estimating treatment effects. Our objective was to evaluate exact matching and propensity score methods by applying them ia 1-year pre-post historical database study to investigate asthma-related outcomes by treatment

    Burden A, Roche N, Miglio C, Hillyer EV, Postma DS, Herings RM, Overbeek JA, Khalid JM, van Eickels D, Price DB. Pragmat Obs Res. 2017 8 15-30.
  • Chemotherapy Exposure and outcomes of Chronic Lymphoid Leukemia PatientsAbstract

    Kuiper J, Musingarimi P, Tapprich C, Penning-van Beest F, Gaudig M. J Clin Intensive Care Med. 2017 2 025-033.
  • Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort studyAbstract

    OBJECTIVES: Estimate and compare the risk of mortality in patients whose antidiabetic therapy is modified to include pioglitazone compared with an alternative antidiabetic medication at the same stage of disease progression. DESIGN: Retrospective chort study. SETTING: Pooled analysis of clinical data collected from primary and/or secondary care settings in four European countries: Finland, The Netherlands, Sweden and the UK

    Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, Majak M, Kool-Houweling L, Linder M, Dolin P, Heintjes EM. BMJ Open Diabetes Res Care. 2017 5 e000364.
  • Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational studyAbstract

    BACKGROUND: Previous studies suggested a relationship between aspirin use and mortality reduction. The mechanism for the effect of aspirin on cancer outcomes remains unclear. The aim of this study was to evaluate aspirin use and survival in patientwith gastrointestinal tract cancer. METHODS: Patients with gastrointestinal tract cancer diagnosed between 1998 and 2011 were included

    Frouws MA, Bastiaannet E, Langley RE, Chia WK, van Herk-Sukel MP, Lemmens VE, Putter H, Hartgrink HH, Bonsing BA, Vande Velde CJ, Portielje JE, Liefers GJ. Br J Cancer. 2017 Jan; 116 (3): 405-413.
  • The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer DiagnosisAbstract

    BACKGROUND: Use of aspirin after diagnosis of colon cancer has been associated with improved survival. Identification of cancer subtypes that respond to aspirin treatment may help develop personalized treatment regimens. The aim of this study was tinvestigate the influence of BRAF and KRAS mutation status on the association between aspirin use and overall survival after colon cancer diagnosis

    Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, Lemmens VE, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ. PLoS One. 2017 12 (1): e0170775.
  • Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohortsAbstract

    BACKGROUND: Preclinical studies have demonstrated that propranolol inhibits several pathways involved in breast cancer progression and metastasis. We investigated whether breast cancer patients who used propranolol, or other non-selective beta-blocers, had reduced breast cancer-specific or all-cause mortality in eight European cohorts

    Cardwell CR, Pottegard A, Vaes E, Garmo H, Murray LJ, Brown C, Vissers PA, O'Rorke M, Visvan athan K, Cronin-Fenton D, DeSchutter H, Lambe M, Powe DG, van Herk-Sukel MP, Gavin A, Friis S, Sharp L, Bennett K. Breast Cancer Res. 2016 Dec 01; 18 (1): 119.
  • Asthma related medication use and exacerbations in children and adolescents with type 1 diabetesAbstract

    OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 1years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System

    Ahmadizar F, Souverein PC, Arets HG, deBoer A, Maitland-van der Zee AH. Pediatr Pulmonol. 2016 Nov; 51 (11): 1113-1121.
  • Drug dispensings among elderly in the year before colon cancer diagnosis versus matched cancer-free controlsAbstract

    WHAT IS KNOWN AND OBJECTIVE: The concomitant use of multiple drugs is common among the general population of elderly. The aim of this study was to provide an overview of which drugs are dispensed to elderly in the year before colon cancer diagnosisand to compare this with cancer-free controls. METHODS: Data from the Eindhoven Cancer Registry were linked to the PHARMO Database Network

    van Erning FN, Zander s MM, Kuiper JG, van Herk-Sukel MP, Maas HA, Vingerhoets RW, Zimmerman DD, deFeyter EP, van dePoll ME, Lemmens VE. J Clin Pharm Ther. 2016 Oct; 41 (5): 538-45.
  • Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort studyAbstract

    OBJECTIVES: To investigate the 5-yr prevalence and incidence rates of cardiovascular medication and cardiovascular disease before and after onset of type 1 diabetes (T1D) in children and adolescents. METHODS: Children and adolescents (<19 yr) with1D (n = 925), defined as those who received at least two insulin prescriptions, and a four times larger reference cohort (n = 3591) with the same age and gender in the Dutch PHARMO Record Linkage System (RLS) were studied in a retrospective cohort studybetween 1999 and 2009

    Ahmadizar F, FazeliFarsani S, Souverein PC, van der Vorst MM, deBoer A, Maitland-van der Zee AH. Pediatr Diabetes. 2016 Sep; 17 (6): 433-40.